---
schema_version: "secwatch.filing_event.v1"
accession: "0001636282-26-000083"
form_type: "8-K"
ticker: "SYRE"
cik: "0001636282"
company_name: "Spyre Therapeutics, Inc."
filed_at: "2026-06-15T12:01:32+00:00"
generated_at: "2026-06-15T12:06:33.699398+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Spyre reports positive Phase 2 topline data for SPY002 in ulcerative colitis; met primary endpoint

## Summary
- SPY002 achieved primary endpoint: 10.7-point RHI reduction (p<0.0001) at 12 weeks.
- Clinical remission rate 33%, endoscopic improvement rate 42%, modified Mayo Score change -3.7.
- Well tolerated; safety profile consistent with TL1A class; no drug-related SAEs.
- Two SAEs (UC exacerbation, heart failure) deemed not drug-related; no deaths.
- Company on track to report SPY003 Part A data in Q3 2026 and enrolling Part B.

## SEC filing metadata
- accession: 0001636282-26-000083
- form_type: 8-K
- ticker: SYRE
- cik: 0001636282
- company_name: Spyre Therapeutics, Inc.
- filed_at: 2026-06-15T12:01:32+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1636282/000163628226000083/0001636282-26-000083-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1636282/000163628226000083/syre-20260615.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001636282-26-000083
- JSON: https://secwatch.observer/filing/0001636282-26-000083.json
- Plain text: https://secwatch.observer/filing/0001636282-26-000083.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.